Amicus Therapeutics - Public Comps and Valuation Multiples

Amicus Therapeutics Overview

About Amicus Therapeutics

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Founded

2002

HQ

Employees

499

Website

amicusrx.com

Sectors

Drug Development & Therapeutics
Regenerative Medicine
BioTech

Financials

LTM Revenue $608M

LTM EBITDA $80.9M

EV

$2.7B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Amicus Therapeutics Financials

As of September 2025, Amicus Therapeutics reported last 12-month revenue of $608M and EBITDA of $80.9M.

In the same period, Amicus Therapeutics generated $533M in LTM gross profit and -$23.4M in net income.

See Amicus Therapeutics valuation multiples based on analyst estimates

Amicus Therapeutics P&L

In the most recent fiscal year, Amicus Therapeutics reported revenue of $528M and EBITDA of $29.4M.

Amicus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Amicus Therapeutics valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$608M	XXX	$528M	XXX	XXX	XXX
Gross Profit	$533M	XXX	$475M	XXX	XXX	XXX
Gross Margin	88%	XXX	90%	XXX	XXX	XXX
EBITDA	$80.9M	XXX	$29.4M	XXX	XXX	XXX
EBITDA Margin	13%	XXX	6%	XXX	XXX	XXX
EBIT	$41.6M	XXX	$34.1M	XXX	XXX	XXX
EBIT Margin	7%	XXX	6%	XXX	XXX	XXX
Net Profit	-$23.4M	XXX	-$56.1M	XXX	XXX	XXX
Net Margin	-4%	XXX	-11%	XXX	XXX	XXX
Net Debt	XXX	XXX	$176M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Amicus Therapeutics including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $608M. EBITDA for the last twelve months was $80.9M. In the most recent fiscal year, Amicus Therapeutics achieved $528M in revenue and $29.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$608M	Analyst estimates available to subscribers	$528M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$533M	Analyst estimates available to subscribers	$475M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	87.8% gross margin	Analyst estimates available to subscribers	90.0% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$80.9M	Analyst estimates available to subscribers	$29.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	13.3% EBITDA margin	Analyst estimates available to subscribers	5.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$41.6M	Analyst estimates available to subscribers	$34.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	6.9% EBIT margin	Analyst estimates available to subscribers	6.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$23.4M	Analyst estimates available to subscribers	-$56.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-3.8% net profit margin	Analyst estimates available to subscribers	-10.6% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$176M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Amicus Therapeutics

This financial data table provides comprehensive performance metrics for Amicus Therapeutics, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Amicus Therapeutics generated $608M in revenue over the last twelve months.
The company achieved $80.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $533M.
Net income over the last twelve months reached -$23.4M.

Fiscal Year Performance

In the most recent fiscal year, Amicus Therapeutics reported $528M in total revenue.
Fiscal year EBITDA was $29.4M.
The company maintained a gross profit margin of 90.0% in the most recent fiscal year.
EBITDA margin for the fiscal year was 5.6%.
Net profit margin reached -10.6% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Amicus Therapeutics. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Amicus Therapeutics Stock Performance

Amicus Therapeutics has current market cap of $2.5B, and EV of $2.7B.

Market Cap Evolution

Amicus Therapeutics Stock Data

As of October 17, 2025, Amicus Therapeutics's stock price is $8.

See Amicus Therapeutics trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.7B	$2.5B	XXX	XXX	XXX	XXX	$-0.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Amicus Therapeutics Valuation Multiples

Amicus Therapeutics's trades at 5.1x EV/Revenue multiple, and 91.5x EV/EBITDA.

See valuation multiples for Amicus Therapeutics and 15K+ public comps

Amicus Therapeutics Financial Valuation Multiples

As of October 17, 2025, Amicus Therapeutics has market cap of $2.5B and EV of $2.7B.

Equity research analysts estimate Amicus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Amicus Therapeutics has a P/E ratio of -106.1x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV (current)	$2.7B	XXX	$2.7B	XXX	XXX	XXX
EV/Revenue	4.4x	XXX	5.1x	XXX	XXX	XXX
EV/EBITDA	33.3x	XXX	91.5x	XXX	XXX	XXX
EV/EBIT	64.6x	XXX	79.0x	XXX	XXX	XXX
EV/Gross Profit	5.0x	XXX	n/a	XXX	XXX	XXX
P/E	-106.1x	XXX	-44.2x	XXX	XXX	XXX
EV/FCF	-548.4x	XXX	-71.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Amicus Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Amicus Therapeutics Margins & Growth Rates

Amicus Therapeutics's last 12 month revenue growth is 21%

Amicus Therapeutics's revenue per employee in the last FY averaged $1.1M, while opex per employee averaged $0.9M for the same period.

Amicus Therapeutics's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Amicus Therapeutics's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Amicus Therapeutics and other 15K+ public comps

Amicus Therapeutics Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	21%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	13%	XXX	6%	XXX	XXX	XXX
EBITDA Growth	141%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-2%	XXX	26%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	65%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.9M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	21%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	84%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial